Robeco Institutional Asset Management
NBIX icon

Robeco Institutional Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Robeco Institutional Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Buy
107,976
+19,959
+23% +$2.96M 0.02% 374
2026
Q1 		$11.6M Sell
88,017
-25,244
-22% -$3.35M 0.02% 414
2025
Q4 		$16.1M Buy
113,261
+85,076
+302% +$12.3M 0.02% 371
2025
Q3 		$3.96M Buy
28,185
+13,087
+87% +$1.77M 0.01% 600
2025
Q2 		$1.9M Sell
15,098
-1,122
-7% -$129K ﹤0.01% 696
2025
Q1 		$1.79M Buy
16,220
+1,586
+11% +$201K ﹤0.01% 724
2024
Q4 		$2M Sell
14,634
-372,648
-96% -$46.1M ﹤0.01% 700
2024
Q3 		$44.6M Buy
387,282
+53,301
+16% +$7.31M 0.09% 215
2024
Q2 		$46M Buy
333,981
+23,756
+8% +$3.26M 0.1% 189
2024
Q1 		$42.8M Buy
310,225
+132,526
+75% +$18.1M 0.09% 212
2023
Q4 		$23.4M Buy
177,699
+23,632
+15% +$2.72M 0.06% 306
2023
Q3 		$17.3M Sell
154,067
-1,096
-0.7% -$115K 0.05% 343
2023
Q2 		$14.6M Sell
155,163
-7,276
-4% -$711K 0.04% 370
2023
Q1 		$16.4M Sell
162,439
-25,765
-14% -$2.68M 0.04% 351
2022
Q4 		$22.5M Buy
188,204
+123,826
+192% +$14.5M 0.06% 291
2022
Q3 		$6.84M Buy
64,378
+55,548
+629% +$5.64M 0.02% 469
2022
Q2 		$861K Buy
8,830
+8,220
+1,348% +$759K ﹤0.01% 716
2022
Q1 		$57K Sell
610
-2,838
-82% -$241K ﹤0.01% 898
2021
Q4 		$294K Buy
3,448
+66
+2% +$6.07K ﹤0.01% 810
2021
Q3 		$324K Hold
3,382
– – ﹤0.01% 808
2021
Q2 		$329K Hold
3,382
– – ﹤0.01% 845
2021
Q1 		$329K Sell
3,382
-709
-17% -$74.3K ﹤0.01% 827
2020
Q4 		$392K Hold
4,091
– – ﹤0.01% 801
2020
Q3 		$393K Buy
4,091
+3,964
+3,121% +$459K ﹤0.01% 778
2020
Q2 		$15K Sell
127
-3,229
-96% -$357K ﹤0.01% 959
2020
Q1 		$290K Buy
3,356
+2,871
+592% +$281K ﹤0.01% 859
2019
Q4 		$52K Buy
+485
New +$50.8K ﹤0.01% 944

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Robeco Institutional Asset Management's NBIX Position: Q2 2026 in Review

Robeco Institutional Asset Management increased its Neurocrine Biosciences (NBIX) stake by 23% in Q2 2026, buying an estimated $2.96M and bringing the position to 107,976 shares worth $18.2M. The position accounts for 0.02% of the portfolio, ranked #374.

Robeco Institutional Asset Management first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. The position peaked at $46M in Q2 2024. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Robeco Institutional Asset Management held 107,976 shares of Neurocrine Biosciences worth $18.2M as of Q2 2026.
  • Robeco Institutional Asset Management bought 19,959 Neurocrine Biosciences shares in Q2 2026, an estimated $2.96M.
  • Neurocrine Biosciences made up 0.02% of Robeco Institutional Asset Management's portfolio in Q2 2026, its #374 holding.
  • Robeco Institutional Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • Robeco Institutional Asset Management's Neurocrine Biosciences position peaked at $46M in Q2 2024.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.